Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ONC-392 |
Trade Name | |
Synonyms | ONC392|ONC 392 |
Drug Descriptions |
ONC-392 is a pH-sensitive monoclonal antibody that targets CTLA4 (CD152), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C173547 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
lutetium Lu 177 vipivotide tetraxetan + ONC-392 | ONC-392 lutetium Lu 177 vipivotide tetraxetan | 0 | 1 |
ONC-392 | ONC-392 | 0 | 2 |
ONC-392 + Pembrolizumab | ONC-392 Pembrolizumab | 0 | 2 |